Cerulean Pharma Inc. (NASDAQ:CERU)‘s stock had its “market perform” rating restated by equities researchers at Leerink Swann in a note issued to investors on Wednesday.

Several other equities analysts also recently issued reports on CERU. Barclays PLC cut their price target on Cerulean Pharma from $5.00 to $2.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 30th. Roth Capital reaffirmed a “buy” rating and set a $2.50 price target (down from $9.00) on shares of Cerulean Pharma in a research report on Thursday, August 18th. Wedbush downgraded Cerulean Pharma from an “outperform” rating to a “neutral” rating in a research report on Thursday, August 18th. Zacks Investment Research downgraded Cerulean Pharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Janney Montgomery Scott cut Cerulean Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, August 18th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.78.

Analyst Recommendations for Cerulean Pharma (NASDAQ:CERU)

Shares of Cerulean Pharma (NASDAQ:CERU) traded up 51.146% during midday trading on Wednesday, reaching $1.029. The company had a trading volume of 13,578,546 shares. Cerulean Pharma has a one year low of $0.67 and a one year high of $4.33. The company’s market capitalization is $28.18 million. The company has a 50-day moving average price of $0.96 and a 200 day moving average price of $2.14.

Cerulean Pharma (NASDAQ:CERU) last posted its earnings results on Thursday, August 4th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.08. Equities analysts anticipate that Cerulean Pharma will post ($1.58) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Cerulean Pharma stock. Bridgeway Capital Management Inc. raised its stake in Cerulean Pharma Inc. (NASDAQ:CERU) by 97.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 202,623 shares of the company’s stock after buying an additional 100,000 shares during the period. Bridgeway Capital Management Inc. owned about 0.74% of Cerulean Pharma worth $430,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.19% of the company’s stock.

Cerulean Pharma Company Profile

Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.

5 Day Chart for NASDAQ:CERU

Receive News & Stock Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related stocks with our FREE daily email newsletter.